Author:
Miller Brian J.,Gowda Vrushab,Segal Jodi B.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference12 articles.
1. Darrow JJ, Avorn J, Kesselheim AS. FDA approval and regulation of pharmaceuticals, 1983–2018. JAMA. 2020;323(2):164–76. https://doi.org/10.1001/jama.2019.20288.
2. Stafford RS, Wagner TH, Lavori PW. New, but not improved? Incorporating comparative-effectiveness into FDA labeling. N Engl J Med. 2009;361:1230–3.
3. O’Connor AB. building comparative efficacy and tolerability into the FDA approval process. JAMA. 2010;303(10):979–80.
4. Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and one or more established medicines are available. European Medicines Agency. 2010. [Accessed 7 Jan 2021] https://www.ema.europa.eu/en/need-active-control-therapeutic-areas-where-use-placebo-deemed-ethical-one-more-established.
5. Choice of Control Group and Related Issues in Clinical Trials E10. International Council on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use July 20, 2000. [Accessed 7 Jan 2021] https://database.ich.org/sites/default/files/E10_Guideline.pdf.